2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cisplatin
50
Capecitabine
42
apatinib
34
Radiotherapy
33
Oxaliplatin
33
Gemcitabine
33
Cyclophosphamide
32
Drug Therapy
31
Paclitaxel
30
Carboplatin
29
tislelizumab
27
Irinotecan
27
Fluorouracil
26
Docetaxel
26
Bevacizumab
23
Surgical Procedures, Operative
21
Nivolumab
19
pembrolizumab
18
fludarabine
18
Radiation
16
Metformin
16
Exercise
16
camrelizumab
15
S 1 (combination)
14
Control Groups
14
Blood Specimen Collection
14
Pemetrexed
13
Standard of Care
12
anlotinib
11
Neoadjuvant Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
dolutegravir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn